225Ac/213Bi Generator Based on Millifluidics Controlled Electrodeposition
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Radioisotopes provide both diagnostic tools and therapeutic treatments for cancer and other diseases. In the US, millions of radioisotope doses are given to patients per year. Radiopharmaceutical generators are widely used to provide such short-lived medical radioisotopes in a clinical setting. These generators work by exploiting chemical differences in a parent/daughter isotope relationship. Actinium-225 (half-life 10 d) is used to provide clinically useful amounts of daughter isotopes 213Bi (46 m). An integrated millifluidic 225Ac/213Bi radiopharmaceutical generator device was engineered to produce 213Bi labeled biomolecules. Using recent LANL successes in additive manufacturing of small-scale fluidic devices, a disposable device was developed that integrates three steps for the production of 213Bi labeled antibodies: 1) 213Bi separation from 225Ac parent, 2) 213Bi antibody labeling, and 3) purification of the labelled antibody.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE National Nuclear Security Administration (NNSA); USDOE Laboratory Directed Research and Development (LDRD) Program
- DOE Contract Number:
- 89233218CNA000001
- OSTI ID:
- 1822690
- Report Number(s):
- LA-UR-21-29374
- Country of Publication:
- United States
- Language:
- English
Similar Records
{sup 225}Ac/{sup 213}Bi biomedical generator
ORNL production of the experimental alpha emitters bismuth-213 and actinium-225 for medical applications